Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment

Core Insights - Bioxytran, Inc. is making significant progress in the development of its antiviral drug ProLectin-M, which is currently under an Investigational New Drug (IND) application with the FDA [1] - ProLectin-M targets the galectin fold on spike proteins of various viruses, including SARS-CoV-2, influenza, and RSV, demonstrating high efficacy in clinical trials [2] - The drug's development aligns with a shift in U.S. health policy, potentially positioning ProLectin-M as a first-line therapy for respiratory infections [3] Development Progress - The company has completed dosing in its dose optimization clinical trial, marking a critical milestone in refining the drug's dosing strategy [1][2] - ProLectin-M has shown a complete response in all subjects by day 7 and an 88% response rate by day 3 in double-blind placebo-controlled trials [2] Technology and Mechanism - Bioxytran's platform utilizes linear complex carbohydrate structures to block galectins, which are proteins that facilitate viral attachment to host cells [4] - Ongoing research is exploring ProLectin-M's efficacy against other viruses, including Epstein-Barr Virus (EBV) [4] Strategic Positioning - The company believes that the redirection of resources away from mRNA vaccines creates a unique opportunity for ProLectin-M to become a first-line therapy for patients without underlying medical conditions [3] - Bioxytran is also advancing other therapeutic programs, including those for stroke treatment, leveraging its proprietary technologies [5]